DENVER, CO — May 6, 2026 — Leads & Copy —
Aimwell Partners Inc. (OTCID:AIMN) has made its live Signal Intelligence feed publicly visible at aimwellbio.com/signals, providing the market with its first look at the continuous monitoring engine behind AimwellBio’s verified intelligence platform. The feed is currently active.
The AimwellBio signal feed monitors 13 independent source streams continuously, including FDA safety actions, drug recalls, drug shortages, clinical trial movements, PubMed research publications, bioRxiv preprints, SEC filings, USPTO patent filings, WHO global outbreak surveillance, EMA regulatory actions, international regulatory divergence, legislative policy shifts, and market sentiment. Each signal is classified by Johari quadrant and assigned a dispatch priority. Since system activation in January, 32 verified signals have been archived.
AimwellBio’s live signal intelligence engine is tracking these sources in real time, raising the question of whether other organizations are seeing what it sees.
AimwellBio monitors 13 independent source streams continuously: FDA safety actions, drug recalls, drug shortages, clinical trial movements, PubMed research publications, bioRxiv preprints, SEC filings, USPTO patent filings, WHO global outbreak surveillance, EMA regulatory actions, international regulatory divergence, legislative policy shifts, and market sentiment.
Each one representing a regulatory action, competitive movement, safety event or clinical trial shift that directly affects pipeline decisions, filing strategies, and capital deployment. Each signal is classified by Johari quadrant and assigned a dispatch priority. Every signal is timestamped, source-traced, and scored for confidence before it reaches a user.
According to Aimwell, the biopharma industry spends $140 billion annually on outsourced intelligence, with the majority of that spend producing static deliverables that are outdated before they are read. AimwellBio states the average time between a regulatory action and when a typical organization becomes aware is 14 days.
AimwellBio provides a feed of 13 source streams with real-time classification and verified signals. The feed is visible at aimwellbio.com/signals.
Aimwell Partners Inc. (AIMN) is the parent company of AimwellBio, a verified intelligence platform for healthcare and biopharma. Its flagship system, AIMWELL Cortex, provides continuous signal monitoring across 13 source streams, hallucination containment, institutional memory, and decision-ready intelligence. The FHIN contributor network builds the world’s most verified biopharma dataset. Headquartered in Miami, FL.
See the live signal feed: aimwellbio.com/signals
Understand what AimwellBio does: aimwellbio.com/understand
FHIN founding cohort: aimwellbio.com/fhin | Investors: aimwellbio.com/investors | Ticker: AIMN
Source: Aimwell Partners Inc.
